A global leader in the making of aerospace, building-control and safety products, Honeywell has received a total of 4 Strong Buys, 10 Buys, and 6 Holds according to CNBC. They have benefited from a steady increase in demand across all major segments. Their extensive work with Boeing generated an increase in their aerospace unit of 8%. We saw Honeywell sign a deal with satellite-operator Immarsat to manufacture equipment for airborne broadband connections, which will last 20 years, and could create up to $2.8 billion in revenues.
Thursday, August 16, 2012
Honeywell 2Q2012
A global leader in the making of aerospace, building-control and safety products, Honeywell has received a total of 4 Strong Buys, 10 Buys, and 6 Holds according to CNBC. They have benefited from a steady increase in demand across all major segments. Their extensive work with Boeing generated an increase in their aerospace unit of 8%. We saw Honeywell sign a deal with satellite-operator Immarsat to manufacture equipment for airborne broadband connections, which will last 20 years, and could create up to $2.8 billion in revenues.
Friday, August 10, 2012
BSX F2Q12 Earnings 6/27/12 - (Ryan Kennedy)
Excluding divested businesses, the firm reported revenues of $1.8bn compared to $1.9bn a year ago. Revenues from Interventional Cardiology, the firm’s stent business, saw the largest drop of 13%, from $652mm to $549mm. The Cardiac Rhythm Management unit, the firm’s ICD and pacemaker unit and also the firm’s second largest division, also fell 8%, from $544mm to $488mm. The CRM division has slowed on decreased procedural volumes, driven by a study in the Journal of the American Medical Association and subsequent Department of Justice investigations into non-evidence based ICD implants. Despite disappointing performance from the business’ two largest segments, BSX continues to have positive growth in its smaller units, which are continually becoming more significant parts of the business. The Neuromodulation unit, which produces implantable electronic devices used to control chronic pain, continued its strong performance, growing from $84mm to $91mm, or 10% on a constant currency basis. The Endoscopy and Peripheral Interventions units also saw moderate growth of 7%, from $298mm to $311mm and $189mm to $196mm, respectively.
BSX continues to make strides in profitability. The firm increased gross margin by 322 bps, from 65% to 68%, as the firm continues its transition from the lower-margin Promus stent to the higher-margin Promus Element. After removing one-time items, EBITDA margin increased 22 bps despite increases in SG&A and R&D as percentages of sales, primarily driven by the increase in gross margin. On an absolute basis, SG&A grew by $6mm, while R&D fell by $10mm and EBITDA dropped $23mm. Boston Scientific continues to pay down debt and reduce interest expense, which has historically weighed on earnings since the firm took on $6.5bn in debt to acquire Guidant in 2006. The firm reported interest expense of $64mm compared to $73mm a year ago. After removing a $3.4bn non-cash goodwill impairment charge associated with the EMEA unit, BSX reported net income of $242mm or $0.17 a share. On a GAAP basis, the company reported a net loss of $3.4bn or $2.39 per share.
Going forward, we are bullish on Boston Scientific. The company has been trading based on revenue growth in the CRM and Interventional Cardiology units, but there is more than meets the eye. Despite contractions in the two main business segments, the company continues to have significant growth in the Neuromodulation and Endoscopy units, which are now becoming sizable portions of the company, and should begin to have a larger effect on the stock price. The company continues to make strides in profitability and unload the debt levels that have suppressed the stock over the past six years. Overall the company is stronger and more financially sound, but needs a catalyst in the IC or CRM units to reawaken the stock and allow investors to focus on improved financials. The PROMUS Element, which has been brought to market but is still in its infancy, may be the catalyst needed to bolster Interventional Cardiology revenues. Aside from the Element, there are very positive new developments in the Cardiac Rhythm Management unit, with the $150mm acquisition of Cameron Health and its subcutaneous S-ICD device. The S-ICD device has the potential to be a $750mm market, and BSX is the only company that has such a device. Considering the firm’s improved health, its strong operating cash flow generation of $407mm, and catalysts in the Element and S-ICD, we are bullish on BSX and believe 2013 will be particularly strong for the firm.
Thursday, August 9, 2012
VZ Sell Thesis
Qualcomm Earnings release
Qualcomm released earnings results on July 19th, posting EPS of 86 cents, which was in-line with expectations. They also posted a 28% increase year over year in revenues at $4.63 billion. Company guidance for the fourth quarter EPS of 78-84 cents came in slightly below the consensus expectations of 89 cents, due to lower projections in smartphone sales. CEO Dr. Paul Jacobs states that their estimates in 3G/4G device shipments have changed as they expect demand “to be more back-end loaded as devices are launched for the holiday season.” They saw margins drop slightly over the quarter, gross margins coming in at 64.4% compared with 64.7% last year, and operating margins at 30.0% compared with 31.0% last year. Sales of their 3G and 3G/4G chipsets have been driving their revenue growth as countries all over the world continue to adopt mobile platforms. They shipped 141 million MSM chip units, up 18% from last year. The approximate selling price of each 3G/4G unit rose from $226 to $232. With the gradual adaptation of 4G LTE handsets in developed markets such as the U.S. and Japan, as well as the overwhelming demand of smartphones in emerging markets Qualcomm is in position to benefit from these macro trends. One factor that shouldn’t be overlooked is the decline in smartphone pricing, which could negatively affect Qualcomm’s margins.
-Ryan Ranado
Verizon Earnings Release
Verizon announced earnings results on July 16th, they reported EPS of 64 cents, a 12.3% increase year over year, which met analysts’ expectations. They posted record highs in operating income margin at 30.8% and EBITDA margin of 49%. The wireless segment increased revenues 7.3% year over year, added 1.2 million retail customers; 888,000 of which were postpaid customers. The wireline segment saw increases of 2.5 percent in revenues, with 65% of revenues generated by Verizon FiOS. Verizon had a 3 percent increase in smartphone users, bringing in 50% of their postpaid revenues from smartphone customers. Verizon released its Share Everything plan on June 28th, offering customers unlimited calling, texting, and shareable data, increasing the amount of devices allowed from 5 to 10. The new plans offer cheaper pricing for customers with more devices, however slightly higher pricing for feature phone customers. They also had the release of the Samsung Galaxy S III which has been a top selling smartphone thus far, which will benefit Verizon’s margins if more customers choose to use that over the iPhone. Looking forward Verizon remains the leading competitor in the 4G LTE market, they have enabled customers to add multiple data devices such as tablets and broadband cards for very affordable rates, and their FiOS services continue to grow and penetrate into new markets. These key points will allow them to grow their business and continue to remain the market leader in mobile telecommunications.
-Ryan Ranado